Abstract: Described embodiments include memory systems that may shadow certain data stored in a first memory device (e.g. NAND flash device) onto a second memory device (e.g. DRAM device). Memory systems may train and/or re-organize stored data to facilitate the selection of data to be shadowed. Initial responses to memory commands may be serviced from the first memory device, which may have a lower latency than the second memory device. The remaining data may be serviced from the second memory device. A controller may begin to access the remaining data while the initial response is being provided from the first memory device, which may reduce the apparent latency associated with the second memory device.

Abstract: Described embodiments include memory systems that may shadow certain data stored in a first memory device (e.g. NAND flash device) onto a second memory device (e.g. DRAM device). Memory systems may train and/or re-organize stored data to facilitate the selection of data to be shadowed. Initial responses to memory commands may be serviced from the first memory device, which may have a lower latency than the second memory device. The remaining data may be serviced from the second memory device. A controller may begin to access the remaining data while the initial response is being provided from the first memory device, which may reduce the apparent latency associated with the second memory device.

Abstract: Described embodiments include memory systems that may shadow certain data stored in a first memory device (e.g. NAND flash device) onto a second memory device (e.g. DRAM device). Memory systems may train and/or re-organize stored data to facilitate the selection of data to be shadowed. Initial responses to memory commands may be serviced from the first memory device, which may have a lower latency than the second memory device. The remaining data may be serviced from the second memory device. A controller may begin to access the remaining data while the initial response is being provided from the first memory device, which may reduce the apparent latency associated with the second memory device.

Abstract: Described embodiments include Memory Systems that may shadow certain data stored in a first memory device (e.g. NAND flash device) onto a second memory device (e.g. DRAM device). Memory systems may train and/or re-organize stored data to facilitate the selection of data to be shadowed. Initial responses to memory commands may be serviced from the first memory device, which may have a lower latency than the second memory device. The remaining data may be serviced from the second memory device. A controller may begin to access the remaining data while the initial response is being provided from the first memory device, which may reduce the apparent latency associated with the second memory device.

Abstract: Described embodiments include memory systems that may shadow certain data stored in a first memory device (e.g. NAND flash device) onto a second memory device (e.g. DRAM device). Memory systems may train and/or re-organize stored data to facilitate the selection of data to be shadowed. Initial responses to memory commands may be serviced from the first memory device, which may have a lower latency than the second memory device. The remaining data may be serviced from the second memory device. A controller may begin to access the remaining data while the initial response is being provided from the first memory device, which may reduce the apparent latency associated with the second memory device.

Abstract: Methods and memories for embedded systems, and systems with managed memories, are provided. In one such method, a managed memory determines when housekeeping operations are indicated, conveys that information to a host, and the host initiates the housekeeping operation at a time determined by the host not to affect real-time system operation.

Abstract: Described embodiments include memory systems that may shadow certain data stored in a first memory device (e.g. NAND flash device) onto a second memory device (e.g. DRAM device). Memory systems may train and/or re-organize stored data to facilitate the selection of data to be shadowed. Initial responses to memory commands may be serviced from the first memory device, which may have a lower latency than the second memory device. The remaining data may be serviced from the second memory device. A controller may begin to access the remaining data while the initial response is being provided from the first memory device, which may reduce the apparent latency associated with the second memory device.

Abstract: A process is provided for producing diastereoisomer A or a pharmaceutically acceptable acid addition salt of 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-(1-benzylpyrrolidin-3-yl) ester 5-methyl ester which comprises subjecting a mixture of diastereoisomers A and B of 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-(1-benzylpyrrolidin-3-yl) ester 5-methyl ester to column chromatography using silica gel as a carrier and a mixture of ethyl acetate and acetic acid as an eluant, and then separating the acetate of diastereoisomer A from the eluate, or treating the acetate with a base, or further treating the resulting diastereoisomer A with a pharmaceutically acceptable acid.

Abstract: A dextro-rotatory optical isomer of diastereoisomer A of (.+-.)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-(1-benzylpyrrolidin-3-yl)ester 5-methyl ester is provided having the formula ##STR1## and wherein the melting point of the hydrochloride of the dextro-rotatory optical isomer is 223.degree. to 230.degree. C. (decomp.), or a pharmaceutically acceptable acid addition salt thereof.

Abstract: The diastereoisomer A of a dihydropyridine-3,5-dicarboxylic acid ester derivative is provided as well as its pharmaceutically acceptable acid addition salts. The invention further discloses a process for producing the compounds and their use as medicaments in imparting vasodilating activity.

Abstract: Various 7-amino-3-substituted-methyl-3-cephem-4-carboxylic acids and lower alkylsily derivatives such as 7-amino-3-(2,3-cyclopenteno-1-pyridiniomethyl)-3-cephem-4 -carboxylic acid iodide and trimethylsilyl 7-trimethylsilylamino-3 -(5,6,7,8-tetrahydro-2-isoquinoliniomethyl)-3-cephem-4 -carboxylate iodide are valuable intermediates in the preparation of new and novel antibacterial agents. A new process for the preparation of these acids and the derivatives has been devised.

Abstract: Various 7-amino-3-substituted-methyl-3-cephem-4-carboxylic acids and lower alkylsilyl derivatives such as 7-amino-3-(2,3-cyclopenteno-1-pyridiniomethyl)-3-cephem-4-carboxylic acid iodide and trimethylsilyl 7-trimethyl-silylamino-3-(5,6,7,8-tetrahydro-2-isoquinoliniomethyl)-3-ceph em-4-carboxylate iodide are valuable intermediates in the preparation of new and novel antibacterial agents. A new process for the preparation of these acids and the derivatives has been devised.

Abstract: Novel cephalosporin compounds of the formula ##STR1## wherein the wavy line means syn-form and anti-form bonds, R.sup.1 represents a cyanomethyl group, a thiocarbamoylmethyl group or an aminothiazolylmethyl group, and A represents a unsubstituted or substituted pyridinio group; and salts thereof. These compounds have excellent antibacterial activities.

Abstract: Novel cephem compounds are provided having the formula: ##STR1## wherein R represents lower alkyl, which may be substituted with lower acyloxy, lower alkylthio or certain 5 or 6-membered heterocyclic ring-containing groups. The cephem compounds and salts thereof exhibit antibacterial activity to many pathogens. A process for producing the cephem compounds is also provided.

Abstract: A cephalosporin derivative of the formula ##STR1## wherein R is a hydrogen atom, a lower alkyl group which may have been substituted or a carbamoyl group which may have been substituted; R.sub.1 is hydrogen atom or a methoxy group; R.sub.2 is a hydrogen atom, an acyloxy group, or a nitrogen-containing 5-membered heterocyclic thio group which may have been substituted; R.sub.3 is a free amino group or an amino group having a protective group; and R.sub.4 is a free carboxy group or a carboxy group having a protective group or the salts thereof.The compound of this invention has an excellent antibacterial activity against gram negative bacteria and gram positive bacteria.

Abstract: Cephalosporin compounds represented by the general formula ##STR1## wherein R represents a group shown by formula ##STR2## wherein R.sup.1 represents a hydrogen atom or a lower alkyl group of 1-3 carbon atoms and R.sup.2 represents a hydrogen atom, a lower alkyl group of 1-3 carbon atoms, a phenyl group which may be substituted by an amino or hydroxy group, a cyano group, a carboxy group, or a carboxymethyl group; said R.sup.1 and R.sup.2 may form a cycloalkylidene group of 4-6 carbon atoms together with the carbon atom to which they are bonded) or a group shown by formula --CH.sub.2 --R.sup.3 (wherein R.sup.3 represents a hydrogen atom, a halogenomethyl group, a carbamoyl group, a carboxymethyl group, .alpha.4-carboxy-3-hydroxyisothiazol-5-yl-thiomethyl group, or .alpha.2-carboxyphenylthiomethyl group); R' represents a group shown by formula ##STR3## (wherein R.sub.a represents a carboxy group, a cyano group, or a carbamoyl group which may be substituted by a lower alkyl group of 1-3 carbon atoms and R.sub.

Abstract: Cephalosporin compounds shown by the general formula ##STR1## wherein R.sub.1 represents hydrogen atom or an amino group; R.sub.2 and R.sub.3, which may be the same or different, each represents hydrogen atom, a hydroxy group, an oxo group, a lower alkyl group, or a lower alkoxy group; R.sub.4 represents a hydrogen atom or a lower alkoxy group; R.sub.5 represents an acetoxy group or --S--R.sub.6 (wherein R.sub.6 represents a 5- or 6-membered nitrogen-containing heterocyclic group which can be substituted by a lower alkyl group or lower alkoxy group); and A represents a monocyclic or bicyclic heterocyclic ring containing one or two atoms selected from the group consisting of nitrogen, oxygen and a sulfur atom; and pharmaceutically acceptable nontoxic salts thereof.These compounds have excellent antimicrobial activity against various microorganisms including resistant bacteria and are used for the treatment of bacterial infections of animals including human beings.

Abstract: The ampicillin derivatives represented by the general formula ##SPC1##Wherein R represents ##SPC2##Wherein R' represents a hydrogen atom, a methyl group, or an ethyl group and A and B each represents a hydrogen atom, a hydroxyl group, a methyl group, a methoxy group, a nitro group, or a halogen atom and further said B may combine with A on the carbon atom at the position to form ##SPC3##Group (where in Z represents --CH=N-- or --CH=CH-- and an R.sup.2 represents a hydrogen atom, a hydroxyl group, a phenyl group, a methyl group, an ethyl group, a methoxy group, an ethoxyl group, a methylthio group, a trifluoromethyl group, a halogen atom, a nitro group, an acetyl group, an acetamido group, a ethoxycarbonyloxy group, or a methylsulfonyl group and further R.sub.2 and ##SPC4##May form a thiazole, isothiazolo, pyrrolo, furo, or benzo fused ring which may be substituted by an oxo group, a methyl group, or an acetyl group) and the dotted line means an arbitrary double bond, ##SPC5##Wherein R.sup.3 and R.sup.

Abstract: The penicillin derivatives represented by the formula ##SPC1##Wherein ring A represents a 5- or 6-membered single or fused ring which may contain one or more nitrogen atoms, an oxygen atom, or a sulfur atom; R.sup.1, R.sup.2, and R.sup.3, which may be the same or different, each represents a hydrogen atom, a hydroxy group, a lower alkyl group, a nitro group, a halogen atom, or an oxo group; and B represents a p-hydroxyphenyl group or a 1,4-cyclohexadien -1-yl group, and their nontoxic pharmaceutically acceptable salts.The compounds are antibiotics having excellent antibacterial activity in particular with respect to the Pseudomonas genus.